1. Scrip
  2. >>Business
  3. >>Deals

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development

 
• By Joseph Haas and Jo Shorthouse

Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.

Morrie Birnbaum of Pfizer
Pfizer's Morris Birnbaum

Smaller companies like Intercept Pharmaceuticals Inc. and Genfit SA are further ahead in the race to bring the first therapy to market in non-alcoholic steatohepatitis (NASH), but Pfizer Inc. and Novartis AG will study their NASH candidates in combination trials in an effort to win what one executive describes as a marathon, rather than a sprint.

The pharma giants announced a partnership Oct. 29 to study Novartis’ Phase II farnesoid X receptor (FXR) agonist tropifexor (LJN452) in combination with three Pfizer candidates that have reached the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.